The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder
Abstract
This randomized, placebo-controlled, double-blind study was the first to evaluate the antidepressant efficacy, safety, and tolerability of an NR2B subunit-selective N-methyl-D-aspartate receptor antagonist, CP-101,606. Subjects had major depression, according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria and a history of treatment refractoriness to least 1 adequate trial of a selective serotonin reuptake inhibitor. The study had 2 treatment periods. In period 1, subjects first received a 6-week open-label trial of paroxetine and a single-blind, intravenous placebo infusion. Period 1 nonresponders (n = 30) then received a randomized double-blind single infusion of CP-101,606 or placebo plus continued treatment with paroxetine for up to an additional 4 weeks (period 2). Depression severity was assessed using the Montgomery-Asberg Depression Rating Scale and 17-item Hamilton Depression Rating Scale. On the prespecified main outcome measure (change from baseline in the Montgomery-Asberg Depression Rating Scale total score at day 5 of period 2), CP-101,606 produced a greater decrease than did placebo (mean difference, 8.6; 80% confidence interval, -12.3 to -4.5) (P < 0.10). Hamilton Depression Rating Scale response rate was 60% for CP-101,606 versus 20% for placebo. Seventy-eight percent of CP-101,606-treated responders maintained response status for at least 1 week after the infusion. CP-101,606 was safe, generally well tolerated, and capable of producing an antidepressant response without also producing a dissociative reaction. Antagonism of the NR2B subtype of the N-methyl-D-aspartate receptor may be a fruitful target for the development of a new antidepressant with more robust effects and a faster onset compared with those currently available and capable of working when existing antidepressants do not.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Glutamate receptor ion channels
Mayer, M. L. (2005) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2005.05.004 · Cited by 3,640
The Glutamate Receptor Ion Channels
Dingledine, R., Borges, K., Bowie, D., & Traynelis, S. F. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01394-2 · Cited by 3,554 · cited 1×
“N-methyl-D-aspartate receptors are tetrameric proteins composed of 2 NR1 subunits and 2 NR2 subunits.(18) There are 4 different NR2 subunits (NR2A-D) that are differentially localized throughout the CNS.”
BackgroundKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Study of a New Schizophrenomimetic Drug—Sernyl
LUBY, E. D. (1959) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1959.02340150095011 · Cited by 921
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2462 · Cited by 894
The role of the hippocampus in the pathophysiology of major depression
Campbell, S., & MacQueen, G. (2004) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0441 · Cited by 880
Functional antagonists at the NMDA receptor complex exhibit antidepressant actions
Trullas, R., & Skolnick, P. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90204-j · Cited by 785
Nierenberg, A. A., Fava, M., Trivedi, M. H., Wisniewski, S. R., Thase, M. E., McGrath, P. J., Alpert, J. E., Warden, D., Luther, J. F., Niederehe, G., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1519 · Cited by 559
Loftis, J. M., & Janowsky, A. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00302-9 · Cited by 362
Fava, M., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Alpert, J. E., McGrath, P. J., Thase, M. E., Warden, D., Biggs, M., Luther, J. F., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.7.1161 · Cited by 362
Rush, A. J. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.2.201 · Cited by 353
McGrath, P. J., Stewart, J. W., Fava, M., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Thase, M. E., Davis, L., Biggs, M. M., Shores-Wilson, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1531 · Cited by 350
Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition
Mott, D. D., Doherty, J. J., Zhang, S., Washburn, M. S., Fendley, M. J., Lyuboslavsky, P., Traynelis, S. F., & Dingledine, R. (1998) · Nature Neuroscience · doi:10.1038/3661 · Cited by 224
The NMDA Antagonist Model for Schizophrenia: Promise and Pitfalls
Abi-Saab, W., D'Souza, D., Moghaddam, B., & Krystal, J. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979354 · Cited by 208
Prolonged effect of an anesthetic dose of ketamine on behavioral despair
Yilmaz, A., Schulz, D., Aksoy, A., & Canbeyli, R. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00693-1 · Cited by 199
Glutamate-based therapeutic approaches: NR2B receptor antagonists
GOGAS, K. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.11.001 · Cited by 175
Potential Antidepressive Properties of Amantadine, Memantine and Bifemelane
Moryl, E., Danysz, W., & Quack, G. (1993) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1993.tb01351.x · Cited by 156
Sigma Receptor Ligands: Possible Application as Therapeutic Drugs and as Radiopharmaceuticals
Ishiwata, K., & Hashimoto, K. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206778559614 · Cited by 145
Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715)
Layer, R. T., Popik, P., Olds, T., & Skolnick, P. (1995) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(95)00155-p · Cited by 137
Oquendo, M. A., Baca‐García, E., Kartachov, A., Khait, V. D., Campbell, C. E., Richards, M., Sackeïm, H. A., Prudic, J., & Mann, J. J. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0714 · Cited by 113
Przegaliński, E., Tatarczynska, E., Dereń-Wesołek, A., & Chojnacka-Wójcik, E. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(96)00157-8 · Cited by 112
Dizocilpine antagonizes the effect of chronic imipramine on learned helplessness in rats
Meloni, D., Gambarana, C., Montis, M. G. D., Pra, P. D., Taddei, I., & Tagliamonte, A. (1993) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(93)90374-3 · Cited by 96
Further characterization of [3H]ifenprodil binding to σ receptors in rat brain
Hashimoto, K., & London, E. D. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90241-9 · Cited by 93
Papp, M., & Moryl, E. (1996) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00675-9 · Cited by 81
Ketamine and the potential role for rapid-acting antidepressant medications
Krystal, J. H. (2007) · Swiss Medical Weekly · doi:10.4414/smw.2007.11932 · Cited by 55
The sigma enigma: can sigma receptors provide a novel target for disorders of mood and cognition?
Stahl, S. (2008) · Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n1101 · Cited by 42
Coughenour, L. L., & Barr, B. M. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29675-0 · Cited by 37
CP‐101,606: An NR2B‐Selective NMDA Receptor Antagonist
Menniti, F. S., Shah, A. K., Williams, S. A., Wilner, K. D., White, W. F., & Chenard, B. L. (1998) · CNS Drug Reviews · doi:10.1111/j.1527-3458.1998.tb00073.x · Cited by 22
Self-citation
Cited by
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568
Self-citationmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Mechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127
Li, N., Liu, R.-J., Dwyer, J. M., Banasr, M., Lee, B., Son, H., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.12.015 · Cited by 1,082
Towards a glutamate hypothesis of depression
Sanacora, G., Treccani, G., & Popoli, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.036 · Cited by 1,036
Metadata
- Authors
- Preskorn, S. H., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2008-12
- Volume
- 28
- Issue
- 6
- Pages
- 631-637
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2047397795
- Cited by
- 518
- References
- 33
- FWCI
- 19.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.